Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,350 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,350 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $22.15, for a total value of $74,202.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total value of $20,259.00.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.

Enliven Therapeutics Trading Up 0.5 %

Shares of NASDAQ ELVN opened at $22.50 on Thursday. The company has a fifty day moving average price of $25.20 and a 200 day moving average price of $24.28. The firm has a market cap of $1.10 billion, a PE ratio of -11.84 and a beta of 1.02. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Quest Partners LLC lifted its stake in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after acquiring an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics in the third quarter worth $256,000. Verition Fund Management LLC acquired a new position in Enliven Therapeutics during the third quarter worth $271,000. Finally, The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics in the second quarter valued at $322,000. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird raised their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Finally, BTIG Research initiated coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of “Buy” and an average target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.